Home › NDC Lookup › RxCUI directory › RxCUI 2558607

Posaconazole 300 MG Powder for Oral Suspension [Noxafil] — RxCUI 2558607

RxNorm drug concept · Semantic branded drug
RxCUI 2558607 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2558607
Official namePosaconazole 300 MG Powder for Oral Suspension [Noxafil]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNoxafil 300 MG Powder for Oral Suspension; Noxafil PowderMix 300 MG Powder for Oral Suspension
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)28 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Posaconazole: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats invasive aspergillosis, a serious mold infection. It also helps prevent serious Aspergillus and Candida infections when your immune system is severely weakened. The oral...
  • Delayed-release tablets can be taken with or without food. The oral suspension should be taken with a full meal. The injection is given by a clinician through a central line over a...
  • The most common are diarrhea, nausea, vomiting, fever, headache, cough and low potassium. Let your care team know if they are bothersome or severe.
  • Call right away for a racing or irregular heartbeat, fainting, signs of liver trouble, rising blood pressure or swelling, or severe vomiting and diarrhea. Those last two can keep t...
📖 Read our full Posaconazole guide →

🕸️ Concept Web — How Posaconazole 300 MG Powder for Oral Suspension [... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Posaconazole 300 MG Powder for Oral Suspension [Noxafil] RxCUI 2558607

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Posaconazole 282446
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Noxafil 356772
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Posaconazole Powder for Oral Suspension 2558602
    • Posaconazole Oral Powder Product 2558601
    • Posaconazole Oral Product 1165109
    • Posaconazole Powder for Oral Suspension [Noxafil] 2558605
    • Noxafil Oral Powder Product 2558606
    • Noxafil Oral Product 1178134
    • Powder for Oral Suspension 1540456
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Posaconazole 300 MG Powder for Oral Suspension SCD · 2558603
  • Posaconazole 300 MG SCDC · 2558600
  • Posaconazole Powder for Oral Suspension SCDF · 2558602
  • Posaconazole Oral Powder Product SCDG · 2558601
  • Posaconazole Oral Product SCDG · 1165109

Brand-Name Concepts

  • Posaconazole 300 MG [Noxafil] SBDC · 2558604
  • Posaconazole Powder for Oral Suspension [Noxafil] SBDF · 2558605
  • Noxafil Oral Powder Product SBDG · 2558606
  • Noxafil Oral Product SBDG · 1178134
  • Noxafil BN · 356772

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2558607 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00085-1328-01 1 BOTTLE, GLASS in 1 CARTON (0085-1328-01) / 105 mL in 1 BO... NOXAFIL Merck Sharp & Dohme LLC 2006-09-15
00085-2224-02 8 PACKET in 1 CARTON (0085-2224-02) / 1 POWDER, FOR SUSPENS... NOXAFIL Merck Sharp & Dohme LLC 2021-06-08
00085-4324-02 60 TABLET, COATED in 1 BOTTLE (0085-4324-02) NOXAFIL Merck Sharp & Dohme LLC 2013-11-25
00085-4331-01 1 VIAL, GLASS in 1 CARTON (0085-4331-01) / 16.7 mL in 1 VIA... NOXAFIL Merck Sharp & Dohme LLC 2014-03-13
Observed labelers: Merck Sharp & Dohme LLC (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.